NTLA: SEC Form 10-Q filed by Intellia Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for NTLA
Across the 27 sessions after earlier NTLA headlines, the stock closed higher 17 times and lower 10 times, with a median move of 4.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NTLA | SPY |
|---|---|---|---|
| Aug 6, 2026 | Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | +2.5% | -0.2% |
| Jul 30, 2026 | Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates | +2.7% | +1.7% |
| Jul 16, 2026 | Intellia Therapeutics downgraded by Wolfe Research with a new price target | -9.0% | -0.5% |
| Jul 7, 2026 | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -2.3% | -0.5% |
| Jun 15, 2026 | Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | +23.2% | +1.8% |
| Jun 8, 2026 | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -0.4% | +0.2% |
Quantisnow market dataNASDAQ
NTLA
Intellia Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Listed since
- 2016
Get push alerts for NTLA
Full NTLA profile on Quantisnow Follow NTLA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time